CA2411542A1 - Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes - Google Patents

Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes Download PDF

Info

Publication number
CA2411542A1
CA2411542A1 CA002411542A CA2411542A CA2411542A1 CA 2411542 A1 CA2411542 A1 CA 2411542A1 CA 002411542 A CA002411542 A CA 002411542A CA 2411542 A CA2411542 A CA 2411542A CA 2411542 A1 CA2411542 A1 CA 2411542A1
Authority
CA
Canada
Prior art keywords
seq
peptide
nls
dna
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411542A
Other languages
English (en)
Inventor
Teni Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411542A1 publication Critical patent/CA2411542A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)

Abstract

L'invention concerne un procédé d'encapsulation de plasmides, d'oligonucléotides ou de médicaments négativement chargés dans des liposomes présentant une composition lipidique différente entre leur bicouches membranaires intérieure et extérieure et capables d'atteindre des tumeurs primaires et leurs métastases après une injection intraveineuse administrée à des animaux et à des humains. Le procédé de formulation comprend une formation de complexe entre l'ADN avec des molécules lipidiques cationiques, et des conjugués de peptides fusogènes/NLS composés d'une chaîne hydrophobe d'environ 10-20 acides aminés et contenant également au moins quatre résidus d'histidine ou NLS au niveau de leur unique extrémité. Les molécules encapsulées présentent une efficacité thérapeutique dans l'éradication d'une variété de tumeurs humaines solides comprenant, notamment, le carcinome mammaire et le carcinome prostatique. Une combinaison de plasmides, d'oligonucléotides ou de médicaments chargés négativement, associée à d'autres médicaments antinéoplasiques (le cis-platine chargé positivement, la doxorubicine) encapsulés dans des liposomes, peut présenter une valeur thérapeutique. Les combinaisons de plasmides, oligonucléotides ou médicaments chargés négativement encapsulés avec HSV-tk plus du ganciclovir encapsulé peuvent également présenter une valeur thérapeutique.
CA002411542A 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes Abandoned CA2411542A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
US60/210,925 2000-06-09
PCT/US2001/018657 WO2001093836A2 (fr) 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes cibles de liposomes

Publications (1)

Publication Number Publication Date
CA2411542A1 true CA2411542A1 (fr) 2001-12-13

Family

ID=22784880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411542A Abandoned CA2411542A1 (fr) 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes

Country Status (8)

Country Link
EP (1) EP1292284A2 (fr)
JP (1) JP2003535832A (fr)
CN (2) CN1254234C (fr)
AU (2) AU2001275423B2 (fr)
CA (1) CA2411542A1 (fr)
MX (1) MXPA02012198A (fr)
TW (1) TWI292324B (fr)
WO (1) WO2001093836A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410807A4 (fr) * 2021-09-30 2025-01-15 Caregen Co., Ltd. Peptide ayant une activité anti-âge et son utilisation

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4624639B2 (ja) * 2000-06-16 2011-02-02 ジーランド ファーマ アクティーゼルスカブ 短い荷電ペプチド鎖によってｎ及び／又はｃ末端が修飾されたペプチド
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
EP1360311B1 (fr) * 2000-08-25 2008-04-09 Aventis Pharmaceuticals Inc. Peptides de penetration de membrane et utilisations associees
AU2002236526B9 (en) 2000-11-15 2008-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
EP1460992B1 (fr) 2001-12-03 2009-03-11 Dor Biopharma, Inc. Compositions a base de micelles inverses et applications
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP2003286198A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 増殖因子等を提示するタンパク質中空ナノ粒子を用いる治療薬剤
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
WO2003097805A2 (fr) 2002-05-15 2003-11-27 California Pacific Medical Center Distribution de composes du type acides nucleiques
EP1530465B2 (fr) 2002-06-26 2015-12-16 MediGene AG Procede de production d'une preparation liposomale cationique contenant un compose lipophile
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
AU2003270102B2 (en) * 2002-08-23 2008-10-02 Medigene Ag Non-vesicular cationic lipid formulations
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP1603535A4 (fr) * 2003-03-18 2008-10-15 Ethicon Inc Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
WO2005031362A2 (fr) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Nouveaux agents antibacteriens et procedes permettant de les identifier et de les utiliser
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
JP4810825B2 (ja) * 2004-12-27 2011-11-09 東洋紡績株式会社 リパーゼ活性測定方法および測定試薬
WO2006086330A2 (fr) * 2005-02-08 2006-08-17 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Compositions pharmaceutiques
JP5067733B2 (ja) * 2005-03-09 2012-11-07 国立大学法人北海道大学 目的物質をミトコンドリア内に送達可能な脂質膜構造体
EP1867726A4 (fr) * 2005-03-24 2008-09-24 Univ Hokkaido Nat Univ Corp Liposome capable de libérer efficacement une substance donnée dans le noyau
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP1790657A1 (fr) * 2005-11-24 2007-05-30 Technische Universität München Peptides transmembranaires commutable de pH pour stimuler la fusion transmembranaire
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3192788A1 (fr) 2006-10-03 2017-07-19 Arbutus Biopharma Corporation Formulations contenant des lipides
EP2086521A2 (fr) * 2006-11-07 2009-08-12 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Nanoparticules auto-assemblées constituées de peptides transmembranaires, et leur application pour une administration intratumorale de médicaments anticancéreux
EP2134365B1 (fr) * 2007-03-21 2019-03-13 Effat Emamian Compositions et procédés d'inhibition de la croissance des cellules tumorales
WO2009002274A1 (fr) * 2007-06-28 2008-12-31 Agency For Science, Technology And Research Peptide cationique servant a liberer un agent dans une cellule
JP2009203174A (ja) * 2008-02-26 2009-09-10 Hokkaido Univ タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2010149785A1 (fr) * 2009-06-26 2010-12-29 Universiteit Gent Liposomes cationiques utilisés pour administrer des composés à poids moléculaire élevé
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
WO2012000104A1 (fr) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Systèmes non liposomaux pour une administration d'acide nucléique
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CN103298826A (zh) 2010-11-15 2013-09-11 特拉维夫大学拉莫特有限公司 用于治疗淀粉样纤维形成相关疾病的二肽类似物
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
CN103429610B (zh) * 2011-03-18 2017-03-01 杜克大学 用于抑制炎症的肽
WO2013006838A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogènes et utilisations de celles-ci
EP3508220A1 (fr) 2011-08-31 2019-07-10 GlaxoSmithKline Biologicals S.A. Liposomes pégylés pour l'administration d'arn codant un immunogène
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
CN105101951B (zh) * 2012-10-29 2021-08-03 新加坡科技研究局 一种用于基因-药物治疗的新型试剂
CN103211762B (zh) * 2013-04-11 2015-01-14 同济大学 诊疗一体化新型杂化胶束及其制备方法
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
BR112017006057B1 (pt) * 2014-09-26 2023-11-21 Universidade Estadual Paulista Júlio De Mesquita Filho - Unesp Composição farmacêutica à base de prostaglandina J2 incorporada em sistemas micelares baseados em poloxâmeros para potencialização das atividades analgésica e anti-inflamatória
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
JP6890836B2 (ja) * 2015-09-17 2021-06-18 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
AU2016342049B2 (en) * 2015-10-22 2023-05-18 Modernatx, Inc. Herpes simplex virus vaccine
CA3024129A1 (fr) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Lipides sulfonamide amines cationiques et lipides amines zwitterioniques amphiphiles
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3672573A4 (fr) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. Préparation d'exosomes thérapeutiques à l'aide de protéines membranaires
AU2018394238A1 (en) 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
EP3732185B1 (fr) * 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugués et préparation et utilisation associées
EP3938379A4 (fr) 2019-03-15 2023-02-22 ModernaTX, Inc. Vaccins à base d'arn contre le vih
EP3962933A1 (fr) * 2019-04-18 2022-03-09 Dana-Farber Cancer Institute, Inc. Ciblage sélectif d'enzymes e1 d'activation de l'ubiquitine et de composés du type ubiquitine par des peptides stabilisés de manière structurale
KR102101179B1 (ko) * 2019-09-20 2020-05-15 건양대학교 산학협력단 유방암유래 암줄기세포의 선택적 표적치료를 위한 나노복합체 제조방법
KR102164218B1 (ko) * 2019-09-24 2020-10-12 코스맥스 주식회사 피부 흡수 증진을 위한 다중층 양이온성 리포좀 및 이의 제조방법
WO2022045009A1 (fr) * 2020-08-24 2022-03-03 国立大学法人山口大学 Composition de traçage de fluide et procédé de traçage de fluide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
CN114762679B (zh) * 2021-01-13 2023-04-07 上海交通大学医学院 一种纳米复合物及其制备方法和用途
CN113406957B (zh) * 2021-05-19 2022-07-08 成都理工大学 基于免疫深度强化学习的移动机器人自主导航方法
CN113546180A (zh) * 2021-05-25 2021-10-26 重庆医科大学 一种具有心肌靶向性的基因递送载体及其制备方法
EP4373945A1 (fr) * 2021-07-19 2024-05-29 Wuhan University Compositions et procédés pour l'administration efficace de polynucléotides à des cellules
EP4230638A1 (fr) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides et compositions à utiliser dans des produits cosmétiques
CN114632062A (zh) * 2022-03-21 2022-06-17 南京大学 一种用于递送核酸药物的中性脂质体及其制备方法和应用
EP4531819A2 (fr) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
FR2754272B1 (fr) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa Procede de preparation de compositions pour le transfert d'acides nucleiques
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410807A4 (fr) * 2021-09-30 2025-01-15 Caregen Co., Ltd. Peptide ayant une activité anti-âge et son utilisation

Also Published As

Publication number Publication date
CN1444472A (zh) 2003-09-24
CN1981873A (zh) 2007-06-20
TWI292324B (en) 2008-01-11
AU7542301A (en) 2001-12-17
JP2003535832A (ja) 2003-12-02
EP1292284A2 (fr) 2003-03-19
WO2001093836A3 (fr) 2002-10-03
WO2001093836A2 (fr) 2001-12-13
CN1254234C (zh) 2006-05-03
MXPA02012198A (es) 2004-08-19
AU2001275423B2 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US9278067B2 (en) Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2001275423B2 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
AU2001275423A1 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
Magar et al. Liposome-based delivery of biological drugs
Yang et al. Recent advances in liposome formulations for breast cancer therapeutics
Paliwal et al. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery
Weissig et al. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems
US7393478B2 (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
Ferreira et al. pH-sensitive liposomes for drug delivery in cancer treatment
Zhen et al. Glycerol monooleate-based nanocarriers for siRNA delivery in vitro
JP6137894B2 (ja) リポソーム−エキソソームハイブリッドベシクル及びその調製法
AU2003205049B2 (en) Efficient nucleic acid encapsulation into medium sized liposomes
Akkewar et al. Liposomes in the targeted gene therapy of cancer: A critical review
PL199201B1 (pl) Pęcherzyk lipidowy, sposób wytwarzania pęcherzyka lipidowego oraz zastosowanie pęcherzyka lipidowego
WO2003057190A1 (fr) Encapsulation efficace d'acides nucleiques dans des liposomes de taille moyenne
Kaneda et al. Development of HVJ envelope vector and its application to gene therapy
Ma et al. Targeted delivery of in situ PCR-amplified Sleeping Beauty transposon genes to cancer cells with lipid-based nanoparticle-like protocells
JP4450656B2 (ja) リポソームからなる遺伝子導入用キャリア
Sharma et al. Liposomes: vesicular system an overview
HK1108834A (en) A method for preparing the micelles and the use of said micelles
JP2007166946A (ja) 標的遺伝子の発現を抑制するための組成物
Palmer Development of stabilized plasmid lipid particles as intracellular gene delivery vehicles
MXPA01006862A (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead